The research company Cessatech reports no revenue for the second quarter. The operating loss decreased slightly.Revenue amounted to DKK 0.0 million (1.2).Operating profit amounted to DKK -3.5 million (-3.6). Profit after tax amounted to DKK -2.8 million (-2.8).Earnings per share amounted to DKK -0.15 (-0.16). Cash flow from operating activities amounted to DKK -3.0 million (-5.5). Cash and cash equivalents amounted to DKK 2.3 million (15.1).During the second quarter, Cessatech continued to develop its strategy and expanded its paediatric portfolio with CT004, which is being developed together with Rigshospitalet. CEO Jes Trygved stated this.Following the quarter, the first commercial batch of CT001 was released in the US, enabling launch activities with selected hospitals. In Europe, Cessatech and Proveca are proceeding with a re-examination following CHMP's negative opinion on KemSu/CT001.Trygved believes that the US launch of CT001 and the expanded development portfolio give the company a strong position ahead of the next development phase.Cessatech, DKK millionQ2-2026Q2-2025ChangeNet revenue0.01.2Operating profit-3.5-3.6Net profit-2.8-2.8Earnings per share, DKK-0.15-0.16Cash flow from operating activities-3.0-5.5Cash and cash equivalents2.315.1-84.8%